Megatin DC Capsule contains a combination of Ampicillin 250 mg and Dicloxacillin 250 mg, both of which are beta-lactam antibiotics belonging to the penicillin group. This formulation is indicated for the treatment of various bacterial infections caused by susceptible strains, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and bone and joint infections. Ampicillin exhibits a broad spectrum of activity against Gram-positive and some Gram-negative bacteria by inhibiting bacterial cell wall synthesis, while Dicloxacillin is specifically effective against penicillinase-producing staphylococci, providing enhanced coverage against resistant strains. The dual action of these agents allows for effective management of mixed infections and those caused by beta-lactamase-producing organisms. Megatin DC Capsule should be administered orally, with dosage and duration tailored according to the severity and type of infection, as well as patient-specific factors such as age and renal function. Caution is advised in patients with a history of hypersensitivity to penicillins or cephalosporins. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypersensitivity reactions. Proper adherence to prescribed therapy is essential to prevent resistance development and ensure optimal therapeutic outcomes.